CN119638835A - 抗klrg1抗体 - Google Patents

抗klrg1抗体 Download PDF

Info

Publication number
CN119638835A
CN119638835A CN202411978380.6A CN202411978380A CN119638835A CN 119638835 A CN119638835 A CN 119638835A CN 202411978380 A CN202411978380 A CN 202411978380A CN 119638835 A CN119638835 A CN 119638835A
Authority
CN
China
Prior art keywords
seq
antibody
antibodies
abc
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202411978380.6A
Other languages
English (en)
Chinese (zh)
Inventor
斯蒂芬诺·V.·古洛
肯尼斯·埃文·汤普森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
Original Assignee
Brigham and Womens Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham and Womens Hospital Inc filed Critical Brigham and Womens Hospital Inc
Publication of CN119638835A publication Critical patent/CN119638835A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN202411978380.6A 2018-09-17 2019-09-06 抗klrg1抗体 Pending CN119638835A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862732329P 2018-09-17 2018-09-17
US62/732,329 2018-09-17
PCT/US2019/050110 WO2020060781A1 (en) 2018-09-17 2019-09-06 Anti-klrg1 antibodies
CN201980060735.4A CN112752580B (zh) 2018-09-17 2019-09-06 抗klrg1抗体

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201980060735.4A Division CN112752580B (zh) 2018-09-17 2019-09-06 抗klrg1抗体

Publications (1)

Publication Number Publication Date
CN119638835A true CN119638835A (zh) 2025-03-18

Family

ID=69887899

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202411978380.6A Pending CN119638835A (zh) 2018-09-17 2019-09-06 抗klrg1抗体
CN201980060735.4A Active CN112752580B (zh) 2018-09-17 2019-09-06 抗klrg1抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201980060735.4A Active CN112752580B (zh) 2018-09-17 2019-09-06 抗klrg1抗体

Country Status (13)

Country Link
US (1) US12365735B2 (https=)
EP (1) EP3852779A4 (https=)
JP (2) JP7654548B2 (https=)
KR (1) KR102934267B1 (https=)
CN (2) CN119638835A (https=)
AU (1) AU2019344524A1 (https=)
BR (1) BR112021004553A2 (https=)
CA (1) CA3113069A1 (https=)
EA (1) EA202190647A1 (https=)
IL (2) IL281594B2 (https=)
MX (2) MX2021003119A (https=)
SG (1) SG11202102114UA (https=)
WO (1) WO2020060781A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020060781A1 (en) 2018-09-17 2020-03-26 Abcuro, Inc. Anti-klrg1 antibodies
WO2022056289A1 (en) * 2020-09-11 2022-03-17 National Jewish Health Methods and compositions for treating respiratory diseases or conditions related to innate lymphoid cells
AU2022246164A1 (en) * 2021-03-26 2023-09-28 The Brigham And Women’S Hospital, Inc. Anti-klrg1 antibodies
WO2022204529A1 (en) 2021-03-26 2022-09-29 Abcuro, Inc. Anti-klrg1 antibodies
WO2024072872A2 (en) * 2022-09-27 2024-04-04 The Brigham And Women's Hospital, Inc. Klrg1 signalling therapy for infectious disease

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
WO2006047350A2 (en) 2004-10-21 2006-05-04 Xencor, Inc. IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
EP1810035A4 (en) 2004-11-10 2010-03-17 Macrogenics Inc GENERATION OF FC ANTIBODY REGIONS FOR EFFECTOR FUNCTION
DK1817340T3 (da) 2004-11-12 2012-08-13 Xencor Inc Fc-varianter med ændret binding til fcrn
WO2006076594A2 (en) 2005-01-12 2006-07-20 Xencor, Inc. Antibodies and fc fusion proteins with altered immunogenicity
CN103536915A (zh) 2006-12-27 2014-01-29 埃默里大学 用于治疗传染病和肿瘤的组合物和方法
HRP20160855T1 (hr) 2008-02-08 2016-09-23 Medimmune, Llc Anti-ifnar1 protutijela sa smanjenim afinitetom fc liganda
ES2624835T3 (es) * 2009-08-06 2017-07-17 Immunas Pharma, Inc. Anticuerpos que se unen específicamente a los oligómeros A beta y uso de los mismos
US10053513B2 (en) 2009-11-30 2018-08-21 Janssen Biotech, Inc. Antibody Fc mutants with ablated effector functions
AU2011295902B2 (en) 2010-09-02 2014-12-04 Vaccinex, Inc. Anti-CXCL13 antibodies and methods of using the same
SG10201602394QA (en) 2011-03-29 2016-05-30 Roche Glycart Ag Antibody FC Variants
WO2012145746A1 (en) 2011-04-21 2012-10-26 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for the treatment of neuromyelitis optica
PL2718322T3 (pl) 2011-06-06 2019-07-31 Novo Nordisk A/S Lecznicze przeciwciała
WO2012176765A1 (ja) 2011-06-24 2012-12-27 株式会社ペルセウスプロテオミクス 抗ヒトｐ－カドへリン（ｃｄｈ３）遺伝子組み換え抗体
RU2687043C2 (ru) 2013-04-29 2019-05-06 Ф. Хоффманн-Ля Рош Аг МОДИФИЦИРОВАННЫЕ АСИММЕТРИЧНЫЕ АНТИТЕЛА, СВЯЗЫВАЮЩИЕ Fc-РЕЦЕПТОР, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
EP3119424A4 (en) 2014-03-19 2017-09-13 MacKay Medical Foundation the Presbyterian Church in Taiwan MacKay Memorial Hospital Immunogenic glycopeptides, composition comprising the glycopeptides and use thereof
WO2016009487A1 (ja) 2014-07-14 2016-01-21 三菱電機株式会社 空気調和装置
WO2017019846A1 (en) 2015-07-30 2017-02-02 Macrogenics, Inc. Pd-1-binding molecules and methods use thereof
EP3352760B1 (en) 2015-09-21 2026-03-11 Aptevo Research and Development LLC Cd3 binding polypeptides
WO2017060144A1 (en) 2015-10-07 2017-04-13 F. Hoffmann-La Roche Ag Bispecific antibodies with tetravalency for a costimulatory tnf receptor
KR102799807B1 (ko) 2015-12-30 2025-04-24 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
WO2017152102A2 (en) 2016-03-04 2017-09-08 Alector Llc Anti-trem1 antibodies and methods of use thereof
WO2017210523A1 (en) * 2016-06-03 2017-12-07 The Brigham And Women's Hospital Klrg1 signaling therapy
AU2017326003A1 (en) * 2016-09-16 2019-04-11 Children's Medical Center Corporation KLRG1 depletion therapy
WO2018140831A2 (en) 2017-01-27 2018-08-02 Silverback Therapeutics, Inc. Tumor targeting conjugates and methods of use thereof
CA3059938A1 (en) 2017-04-14 2018-10-18 Kodiak Sciences Inc. Complement factor d antagonist antibodies and conjugates thereof
US20180371088A1 (en) 2017-06-22 2018-12-27 Development Center For Biotechnology TARGET CELL-DEPENDENT T CELL ENGAGING AND ACTIVATION ASYMMETRIC HETERODIMERIC Fc-ScFv FUSION ANTIBODY FORMAT AND USES THEREOF IN CANCER THERAPY
US20210002373A1 (en) 2018-03-01 2021-01-07 Nextcure, Inc. KLRG1 Binding Compositions and Methods of Use Thereof
WO2020060781A1 (en) 2018-09-17 2020-03-26 Abcuro, Inc. Anti-klrg1 antibodies
EP3952999A4 (en) 2019-04-09 2023-01-25 Abcuro, Inc. Killer cell lectin-like receptor subfamily g member 1 (klrg1) depleting antibodies
AU2022246164A1 (en) 2021-03-26 2023-09-28 The Brigham And Women’S Hospital, Inc. Anti-klrg1 antibodies

Also Published As

Publication number Publication date
IL323170A (en) 2025-11-01
MX2021003119A (es) 2021-05-14
AU2019344524A1 (en) 2021-03-25
WO2020060781A1 (en) 2020-03-26
CN112752580A (zh) 2021-05-04
KR20210060477A (ko) 2021-05-26
IL281594A (en) 2021-05-31
MX2025008993A (es) 2025-09-02
JP2024156878A (ja) 2024-11-06
EP3852779A1 (en) 2021-07-28
JP7654548B2 (ja) 2025-04-01
CA3113069A1 (en) 2020-03-26
JP2022501065A (ja) 2022-01-06
IL281594B2 (en) 2026-02-01
EA202190647A1 (ru) 2021-09-09
EP3852779A4 (en) 2022-06-08
US12365735B2 (en) 2025-07-22
US20210347899A1 (en) 2021-11-11
BR112021004553A2 (pt) 2021-06-08
SG11202102114UA (en) 2021-04-29
IL281594B1 (en) 2025-10-01
CN112752580B (zh) 2024-12-13
KR102934267B1 (ko) 2026-03-05

Similar Documents

Publication Publication Date Title
CN112752580B (zh) 抗klrg1抗体
JP4511943B2 (ja) Ｐｄ−１に対する抗体およびその使用
JP4606739B2 (ja) 新規抗ｉｇｆ−ｉｒ抗体およびその使用
JP7368453B2 (ja) Ｐｄ－１およびｌａｇ－３に対する高親和性抗体ならびにそれらから作製された二重特異性結合タンパク質
CN114728065A (zh) 针对cd3和bcma的抗体和自其制备的双特异性结合蛋白
KR20200061320A (ko) 세포독성 t-림프구-관련 단백질 4 (ctla-4)에 대한 신규의 단일클론 항체
WO2007110648A1 (en) Agonist antibodies against tshr
CN113474362A (zh) 对cd44特异性的抗体
US20050142137A1 (en) Antibodies against secretoryleukocyte protease inhibitor
EP3137501A2 (en) Ion channel modulators and uses thereof
KR20210042091A (ko) 항-l1cam 항체 및 이의 용도
CN113423425A (zh) 靶向外泌体的双特异性抗体
EA049153B1 (ru) Антитела к klrg1
KR101996627B1 (ko) Vcam-1-d6에 결합하는 항체 및 그 용도
HK40067877A (en) Antibodies to cd3 and bcma, and bispecific binding proteins made therefrom
HK40061374A (en) Antibodies specific to cd44
HK40060740A (en) Exosome-targeting bispecific antibodies
HK1083510B (en) Antibodies against pd-1 and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination